In B04 the Knapp group will generate a comprehensive chemical probe set for the development of new treatment strategies for SCLC. The chemical probe set will comprise more than hundred highly selective comprehensively characterized small molecules that target epigenetic modulators of the epigenetic code. The aim is to identify at least 3 new targets for the development of drugs by these screening experiments, which will be validated using CRISPR/Cas9 deletion studies.
Professor of Pharmaceutical Chemistry (W3) and site head SGC (Structural Genomics Consortium Frankfurt)
Institute for Pharmaceutical Chemistry